

**From:** Wood, Lorraine  
**Sent:** Friday, May 04, 2018 2:04 PM  
**To:** MaryAnn Lamb <MaryAnn.Lamb@bpl-us.com>  
**Subject:** BLA 125644 Package Insert Labeling Edits: Response Requested by 5/8/18  
**Importance:** High

Dear Mary Ann,

Attached is the WORD version of the changes suggested by the review committee for BLA 125644. The attached label is for the Albuminex 25% but should be applied to Albuminex 5% as well. If these changes are acceptable, please re-submit this updated package insert to STN 125644 after BPL have reviewed it and have taken responsibility for the following:

1. Correcting any spelling, grammar, usage, or formatting errors.
2. Correcting content, if there is a reason for making a change, in which case the reason should be stated.
3. Updating the Table of Contents
4. Updating (adding, deleting) the references in the reference section.
5. Make corresponding changes in the Albuminex 5% label, where appropriate.

Please submit the updated labels for Albuminex 5% and Albuminex 25% by COB Tuesday May 8, 2018.

Thank you  
Lorraine

**Lorraine D. Wood, MS, MLS(ASCP)<sup>CM</sup>**  
*Regulatory Project Manager*

Center for Biologics Evaluation and Research  
Office of Blood Research and Review  
U.S. Food and Drug Administration  
Tel: 240-402-8439  
[lorraine.wood@fda.hhs.gov](mailto:lorraine.wood@fda.hhs.gov)



**THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.**